
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
GLEN | NSE | INR | Real-time | |
GLENc1:NS | NSE | INR | Delayed | |
GLENc2:NS | NSE | INR | Delayed | |
GLEN | BSE | INR | Delayed |
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/nasal sprays. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific engagement by antibodies based on the T cell receptor trispecific antibody, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 bispecific engagement by antibodies based on the T cell receptor biparatopic bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma and acute myeloid leukemia; and GRC 65327, a Cbi-b inhibitor, which is in pre-clinical study for the indication of solid tumors. The company’s pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a telazorlimab OX40 antagonist antibody that is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
Name | Age | Since | Title |
---|---|---|---|
Glenn Mario Saldanha | 54 | 1998 | Chairman, MD & CEO |
Dipankar Bhattacharjee | 63 | 2020 | Independent Non-Executive Director |
Blanche Elizabeth Saldanha | 85 | 2005 | Non Executive Director |
Vijayalakshmi Rajaram Iyer | 70 | 2023 | Independent Non-Executive Director |
Cherylann Maria Pinto | 58 | 1999 | Executive Director of Corporate Services & Executive Director |
Anurag Mantri | 54 | 2025 | Global CFO & Executive Director |
Cyril Konto | - | 2024 | President, CEO & Executive Director of IGI |
Sona Saira Gonsalves Ramasastry | 49 | 2019 | Independent Non-Executive Director |
Pradeep Kumar Sinha | 71 | 2025 | Additional Non-Executive & Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review